ファーマナビゲーター　利尿薬編

出版社： メディカルレビュー社
著者：
発行日： 2007-11-01
分野： 薬学  >  薬剤学
ISBN： 9784779201929
シリーズ： ファーマナビゲーター
電子書籍版： 2007-11-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

3,080 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

商品紹介

本書は利尿薬の薬理作用を病態生理学的見地からコンパクトにまとめたState-of-the-Artである。さらに、臨床における使用の実際もまとめてある。本書により、利尿薬は単に尿量を増加させるために漠然と使用する薬剤ではなく、その特徴と病態生理を理解したうえで使用すべき薬剤であることが理解していただけるであろう。

目次

  • ファーマナビゲーター　利尿薬編

    ―目次―

    Chapter 1　分類と適応
    　分類と適応

    Chapter 2　薬理作用，作用部位
    　薬理作用と使用の原則

    Chapter 3　病態と治療
    　1.本態性高血圧
    　2.脳
    　3.心臓
    　4.腎臓
    　5.血管
    　6.糖尿病合併
    　7.脂質代謝異常合併
    　8.高齢者高血圧
    　9.電解質異常

    hapter 4　EBM
    　利尿薬に関する最近のエビデンスと世界のガイドライン

    Chapter 5　併用療法
    　1.Ca拮抗薬
    　2.ACE阻害薬
    　3.ARB
    　4.β遮断薬
    　5.アスピリン

    Chapter 6　症例の実際（Q&A）

    Chapter 7　使用上の注意・薬物相互作用
    　使用上の注意・薬物相互作用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter1 分類と適応

P.29 掲載の参考文献
1) Williams B, Poulter NR, Brown MJ et al; BHS guidelines working party, for the British Hypertension Society:British Hypertension Society guidelines for hypertension management 2004 (BHS-IV):summary. BMJ 328:634-640, 2004
PubMed
2) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004, pp19
 
3) Pitt B, Zannad F, Remme WJ et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999
 
4) Pitt B, Remme W, Zannad F et al:Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003
PubMed
5) Ruzicka M, Leenen FH:Combination therapy as first-line treatment of arterial hypertension. Can J Cardiol 18:1317-1327, 2002
PubMed
6) Dezii CM:A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 9 (Suppl 9):2-6, 2000
 

Chapter2 薬理作用, 作用部位

P.51 掲載の参考文献
1) Wilcox CS:New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798-805, 2002
PubMed
2) Kwon TH, Frokiaer J, Fernandez-Llama P et al:Altered expression of Na transporters NHE-3, NaPi-II, Na-K-ATPase, BSC-1, and TSC in CRF rat kidneys. Am J Physiol 277 (2 Pt 2):F 257-F 270, 1999
 
3) Nogae S, Michimata M, Kanazawa M et al:Cardiac infarcts increase sodium transporter transcripts (rBSC1) in the thick ascending limb of Henle. Kidney Int 57:2055-2063, 2000
PubMed
4) Volpe M, Magri P, Rao MA et al:Intrarenal determinants of sodium retention in mild heart failure:effects of angiotensin-converting enzyme inhibition. Hypertension 30 (2 Pt 1):168-176, 1997
 
5) Schrier RW, Abraham WT:Hormones and hemodynamics in heart failure. N Engl J Med 341:577-585, 1999
PubMed
6) Shipley RE, Study RS:Changes in renal blood flow, extraction of inulin, glomerular filtration rate, tissue pressure and urine flow with acute alterations of renal artery blood pressure. Am J Physiol 167:676-688, 1951
PubMed
7) 伊藤貞嘉:尿はなぜ作られる-暴飲暴食が可能なわけ-:腎疾患のとらえかた-眼でみるベッドサイドの病態生理. 文光堂, 東京, 2003, pp7-18
 
8) 伊藤貞嘉:二次性高血圧. メディカルレビュー社, 東京, 2003
 
9) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004
 
10) 伊藤貞嘉:特集 心腎疾患の病態と対策. 心血管疾患と腎疾患の連関. 血圧 14;260-265, 2007
 

Chapter3 病態と治療

P.57 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004
 
2) Conway J, Lauwers P:Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 21:21-27, 1960
PubMed
3) SHEP Cooperative Research Group:Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA 265:3255-3264, 1991
 
4) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA 288:2981-2997, 2002
PubMed
5) Psaty BM, Lumley T, Furberg CD et al:Health outcomes associated with various antihypertensive therapies used as first-line agents:a network meta-analysis. JAMA 289:2534-2544, 2003
PubMed
6) National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003
 
7) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
PubMed
8) Zhang H, Thijs L, Staessen JA:Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 48:187-195, 2006
PubMed
9) Dahlof B, Sever PS, Poulter NR et al:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial Lancet 366:895-906, 2005
PubMed
P.65 掲載の参考文献
1) 小林祥泰, 森悦郎, 鈴木昭文ほか:3. 脳卒中一般の発症予防. 脳卒中治療ガイドライン (篠原幸人, 吉本高志, 福内靖男ほか編). 協和企画, 東京, 2004, pp16-17
 
2) PATS Collaborating Group:Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 108:710-717, 1995
 
3) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
PubMed
4) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT) . JAMA 288:2981-2997, 2002
 
5) Numabe A, Uehara Y, Hirawa N et al:Effects of thiazide diuretic on vascular eicosanoid system of spontaneously hypertensive rats. J Hypertens 7:493-499, 1989
PubMed
6) Kaste M, Roine RO:Chapter 51. General Stroke Management and Stroke Units. Stroke:Pathophysiology, Diagnosis And Management (Mohr JP, Choi DW, Grotta JC et al eds) Churchill Livingstone, Philadelphia, 2004, pp 975-977
 
7) Xi G, Keep RF, Hoff JT:Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 5:53-63, 2006
PubMed
8) Davies DC:Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 200:639-646, 2002
PubMed
9) Tao RC, Kelley RE, Yoshimura NN et al:Glycerol:its metabolism and use as an intravenous energy source. JPEN J Parenter Enteral Nutr 7:479-488, 1983
PubMed
10) Broderick JP, Hacke W:Treatment of acute ischemic stroke:Part II:neuroprotection and medical management. Circulation 106:1736-1740, 2002
PubMed
11) Vorstrup S:Tomographic cerebral blood flow measurements in patients with ischemic cerebrovascular disease and evaluation of the vasodilatory capacity by the acetazolamide test. Acta Neurol Scand S 114:1-48, 1988
 
12) Widder B:Cerebral vasoreactivity. Cerebrovascular Ultrasound Theory, practice and future developments (Hennerici MG, Meairs SP) Cambridge University Press, Cambridge, 2001, pp 325-334
 
13) Powers WJ, Raichle ME:Positron emission tomography and its application to the study of cerebrovascular disease in man. Stroke 16:361-376, 1985
 
14) Millichap JG, Woodbury DM, Goodman LS:Mechanism of the anticonvulsant action of acetazoleamide, a carbonic anhydrase inhibitor. J Pharmacol Exp Ther 115:251-258, 1955
PubMed
P.72 掲載の参考文献
1) Crowley SD, Gurley SB, Herrera MJ et al:Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 103:17985-17990, 2006
PubMed
2) Sarnak MJ, Levey AS, Schoolwerth AC et al:Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:215-2169, 2003
 
3) 急性心不全治療ガイドライン (2006年改訂版) (日本循環器学会ホームページ http://www.j-circ.or.jp/guideline/index.htm)
 
4) 慢性心不全治療ガイドライン (2005年改訂版) (日本循環器学会ホームページ http://www.j-circ.or.jp/guideline/index.htm)
 
P.80 掲載の参考文献
1) Sarnak MJ, Levey AS, Schoolwerth AC et al:Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42:1050-1065, 2003
PubMed
2) Ardaillou R, Dussaule JC:Role of a trial natriuretic peptide in the control of sodium balance in chronic renal failure. Nephron 66:249-257, 1994
 
3) Lohmeier TE, Hildebrandt DA, Hood WA:Renal nerves promote sodium excretion during long-term increases in salt intake. Hypertension 33 (1 Pt 2):487-492, 1999
 
4) Brewster UC, Setaro JF, Perazella MA:The renin-angiotensin aldosterone system:cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326:15-24, 2003
PubMed
5) Schrier RW:Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1) . N Engl J Med 319:1065-1072, 1988
PubMed
6) Andreucci M, Russo D, Fuiano G et al:Diuretics in renal failure. Miner Electrolyte Metab 25:32-38, 1999
PubMed
7) Rudy DW, Voelker JR, Greene PK et al:Loop diuretics for chronic renal insufficiency:a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 115:360-366, 1991
PubMed
8) Knauf H, Mutschler E:Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 26:394-400, 1995
PubMed
9) Ninomiya T, Kiyohara Y, Kubo M et al:Chronic kidney disease and cardiovascular disease in a general Japanese population:the Hisayama Study. Kidney Int 68:228-236, 2005
 
10) 松本 朗, 鈴木洋通, 猿田享男:フロセミド抵抗性浮腫に対するトリパミド (ノルモナール) の併用療法. 診断と治療 82:1041-1045, 1994
 
P.88 掲載の参考文献
1) Calder JA, Schachter M, Sever PS:Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol 220:19-26, 1992
 
2) Colas B, Slama M, Masson H et al:Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol 14:363-368, 2000
PubMed
3) Zhu Z, Zhu S, Liu D et al:Thiazide-like diuretics attenuate agonistinduced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 45:233-239, 2005
PubMed
4) Pickkers P, Russel FG, Thien T et al:Only weak vasorelaxant properties of loop diuretics in isolated resistance arteries from man, rat and guinea pig. Eur J Pharmacol 466:281-287, 2003
PubMed
5) Nagata D, Takahashi M, Sawai K et al:Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48:165-171, 2006
PubMed
6) Keidar S, Kaplan M, Pavlotzky E et al:Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development:a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109:2213-2220, 2004
PubMed
7) Rocha R, Rudolph AE, Friedich GE et al:Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H 1802-H 1810, 2002
 
8) Celik T, Iyisoy A, Kursaklioglu H et al:Eplerenone suppresses neointima after coronary stenting in pigs:could it be extrapolated to stent restenosis in humans? Int J Cardiol 115:97-98, 2007
PubMed
P.95 掲載の参考文献
1) UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
Medical*Online
2) SHEP Cooperative Research Group:Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA 265:3255-3264, 1991
 
3) Franse LV, Pahor M, Di Bari M et al:Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 35:1025-1030, 2000
PubMed
4) Franse LV, Pahor M, Di Bari M et al:Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) J Hypertens 18:1149-1154, 2000
PubMed
5) Inaba M, Noguchi Y, Yamamoto T et al:Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res 827:141-145, 2004
PubMed
6) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA 288:2981-2997, 2002
PubMed
7) Whelton PK, Barzilay J, Cushman WC et al:Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia:Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT) . Arch Intern Med 165:1401-1409, 2005
PubMed
8) SHEP Collaborative Research Group:Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29-35, 2005
 
P.97 掲載の参考文献
1) Marre M, Puig JG, Kokot F et al:Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes. The NESTOR study. J Hypertens 22:1613-1622, 2004
PubMed
P.102 掲載の参考文献
1) Kannel WB:Risk stratification in hypertension:new insights from the Framingham Study. Am J Hypertens 13 (1 Pt 2):3S-10S, 2000
 
2) Neaton JD, Wentworth D:Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152:56-64, 1992
 
3) Halperin RO, Sesso HD, Ma J et al:Dyslipidemia and the risk of incident hypertension in men. Hypertension 47:45-50, 2006
PubMed
4) SHEP Cooperative Research Group:Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA 265:3255-3264, 1991
 
5) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA 288:2981-2997, 2002
PubMed
6) Sever PS, Dahlof B, Poulter NR et al:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomized controlled trial. Lancet 361:1149-1158, 2003
 
P.111 掲載の参考文献
1) 上原譽志夫:利尿薬の種類と薬理作用. Jpn Pharmacol Ther (薬理と治療) 31:641-649, 2003
 
2) 上原譽志夫:利尿薬の特徴と使用法. 診断と治療 94:406-411, 2006
Medical*Online
3) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997, 2002
PubMed
4) Wing LM, Reid CM, Ryan P et al;Second Australian National blood Pressure Study Group:A comparison of outcomes with angiotensin-converting-enzyme inhibitor and diuretic for hypertension in the elderly. N Engl J Med 348:583-592, 2003
 
5) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:a meta-analysis. Lancet 358:1305-1315, 2001
PubMed
6) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
PubMed
7) ADVANCE Collaborative Group:Effects of a fix combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial. Lancet 370:829-840, 2007
 
P.119 掲載の参考文献
1) 伊藤貞嘉 編:腎疾患のとらえかた. 文光堂, 東京, 2003
 
2) 木村時久, 太田耕造:高齢者の電解質代謝異常と精神神経症状. 老年神経医学雑誌 16:672-680, 2005
 
3) Loffing J:Paradoxical antidiuretic effect of thiazides in diabetes insipidus:another piece in the puzzle. J Am Soc Nephrol 2004; 15:2948-2950
 

Chapter4 EBM

P.138 掲載の参考文献
1) Psaty BM, Lumley T, Furberg CD et al:Health outcomes associated with various antihypertensive therapies used as first-line agents:a network meta-analysis. JAMA 1289:2534-2544, 2003
 
2) Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus:results of prospectively designed overviews of randomized trials. Arch Intern Med 165:1410-1419, 2005
PubMed
3) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA 288:2981-2997, 2002
PubMed
4) Neaton JD, Grimm RH Jr, Prineas RJ et al:Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 270:713-724, 1993
 
5) Liebson PR, Grandits GA, Dianzumba S et al:Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapyin the Treatment of Mild Hypertension Study (TOMHS) . Circulation 91:698-706, 1995
 
6) 木村玄次郎:高血圧治療と利尿薬. 呼吸と循環 54:71-80, 2006
 
7) Uzu T, Kimura G:Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100:1635-1638, 1999
PubMed
8) Saito F, Kimura G:Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 27:914-918, 1996
PubMed
9) Wassertheil-Smoller S, Psaty B, Greenland P et al:Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 292:2849-2859, 2004
PubMed
10) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
PubMed
11) Carey PA, Sheridan DJ, de Cordoue A et al:Effect of indapamide on left ventricular hypertrophy in hypertension:ameta-analysis. Am J Cardiol 77:17b-19b, 1996
 
12) 沼部敦司, 上原譽志夫, 八木繁ほか:高血圧自然発症ラットの血管壁エイコサノイド系に及ぼすサイアザイド系利尿薬の影響とその作用機序. 日本腎臓学会雑誌 30:1339-1347, 1988
 
13) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
PubMed
14) Brenner BM, Cooper ME, de Zeeuw D et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
PubMed
15) 猿田享男:日本における降圧薬合剤の歴史・変遷-ARB/利尿薬合剤誕生の経緯-. 血圧 13:1297-1300, 2006
Medical*Online
16) 斉藤郁夫:ARB/利尿薬合剤と服薬コンプライアンス. 血圧 13:1354-1357, 2006
 
17) Conlin PR, Spence JD, Williams B et al:Angiotensin II antagonists for hypertension:are there differences in efficacy? Am J Hypertens 13 (4 Pt 1):418-426, 2000
 
18) 福岡富和, 大蔵隆文, 檜垣實男:利尿薬とR-A系抑制薬の併用治療の評価. 循環器科 55:235-242, 2004
 
19) Kostis JB, Wilson AC, Freudenberger RS et al:Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29-35, 2005
 
20) Barzilay JI, Davis BR, Cutler JA et al:Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment:a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . Arch Intern Med 166:2191-2201, 2006
PubMed
21) 日本高血圧学会高血圧治療ガイドライン作成委員会 (猿田享男委員長):高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004
 
22) American Diabetes Association:Standards of medical care in diabetes-2007. Diabetes Care 30 (suppl 1):S 4-S 41, 2007
 
23) Chobanian AV, Bakris GL, Black HR et al:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure:the JNC 7 Report. JAMA 289:2560-2572, 2003
PubMed
24) Mancia G, De Backoer G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guideline for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens 25:1105-1187, 2007
 

Chapter5 併用療法

P.147 掲載の参考文献
1) Wassertheil-Smoller S, Psaty B, Greenland P et al:Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 292:2849-2859, 2004
PubMed
2) Neldam S, Edwards C ; ATHOS Study Group:Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension:results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 115:151-160, 2006
 
3) Julius S, Kjeldsen SE, Weber M et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet 363:2022-2031, 2004
 
4) Palatini P, Mugellini A, Spagnuolo V et al:Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study) . Blood Press Monit 9:91-97, 2004
PubMed
5) Oparil S, Barr E, Elkins M et al:Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 18:608-625, 1996
 
6) Chrysant SG, Chrysant C, Trus J et al:Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Am J Hypertens 2:537-541, 1989
PubMed
7) Burris JF, Weir MR, Oparil S et al:An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA 263:1507-1512, 1990
PubMed
8) Schoenberger JA, Glasser SP, Ram CV et al:Comparison of nitrendipine combined with low-dose hydrochlorothiazide to hydrochlorothiazide alone in mild to moderate essential hypertension. J Cardiovasc Pharmacol 6 (suppl 7):S 1105-S 1108, 1984
 
9) Damasceno A, Caupers P, Rafik A et al:[The additional efficacy of the nifedipine-diuretic combination depends on the potency of the drug administered first and not the sequence of administration. A double blind study in salt-sensitive black hypertensives] Rev Port Cardiol 18:9-19, 1999
 
P.152 掲載の参考文献
1) 伊藤貞嘉:ARB/利尿薬合剤の相乗効果メカニズムについて. 血圧 13:26-29, 2006
 
2) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004, pp31
 
3) Franse LV, Pahor M, Di Bari M et al:Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 35:1025-1030, 2000
PubMed
4) Sato A, Saruta T:Aldosterone breakthrough during angiotensin-converting enzyme inhinitor therapy. Am J Hypertens 16 (9 Pt 1):781-788, 2003
 
5) The Enalapril-Hydrochlorothiazide in Essential Hypertension Canadian Working Group:Enalapril and enalapril-hydrochlorothiazide in the treatment of essential hypertension. Clin Ther 15:364-373, 1993
 
6) Middlemost SJ, Tager R, Davis J et al:Effectiveness of enarapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 73:1092-1097, 1994
 
7) PROGRESS Collaborative Group:Randomised trial of a periodopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
PubMed
8) 宮森勇:臨床上, 利尿剤の臓器保護効果はどのように評価されるか. 血圧 9:45-48, 2002
 
P.157 掲載の参考文献
1) MacKay JH, Arcuri KE, Goldberg AI et al:Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 156:278-285, 1996
PubMed
2) Zillich AJ, Garg J, Basu S et al:Thiazide diuretics, potassium, and the development of diabetes:a quantitative review. Hypertension 48:219-224, 2006
PubMed
3) Nakashima M, Uematsu T, Kosuge K et al:Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42:333-335, 1992
PubMed
4) Lacourciere Y, Poirier L:Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 16:1036-1042, 2003
PubMed
5) Dahlof B, Devereux RB, Kjeldsen SE et al; LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol Lancet 359:995-1003, 2002
 
6) Lithell H, Hansson L, Skoog I et al; SCOPE Study Group:The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double-blind intervention trial J Hypertens 21:875-886, 2003
 
7) Julius S, Kjeldsen SE, Weber M et al; VALUE trial group:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet 363:2022-2031, 2004
 
8) 荒川規矩男:ARBを基礎薬とした場合の併用薬. 臓器保護を考慮したチャート式 高血圧併用療法, (堀内正嗣, 浦信行, 北風政史ほか編) メディカルレビュー社, 東京, 2005, pp56-57
 
P.164 掲載の参考文献
1) Mancia G, De Backer G, Dominiczak A et al:2007 Guidelines for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens 25:1105-1187, 2007
 
2) Khan NA, McAlister FA, Robkin SW et al:The 2006 Canadian Hypertension Education Progrom recommendations for the man agement of hypertension:Part II-Therapy. Can J Cardiol 22:583-593, 2006
 
3) National Collaborating Centre for Chronic Conditions:Hypertension:management of hypertension in adults in primary care:partial update. London , Royal College of Physicians, 2006
 
4) Swedberg K, Cleland J, Dargie H et al; Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology:Guidelines for the diagnosis and treatment of chronic heart failure:executive summary (update 2005) . Eur Heart J 26:1115-1140, 2005
 
5) Ryden L, Standl E, Bartnik M et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD):Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:executive summary. Eur Heart J 28:88-136, 2007
 
P.169 掲載の参考文献
1) Hennekens CH, Dyken ML, Fuster V:Aspirin as a therapeutic agent in cardiovascular disease:a statement for healthcare professionals from the American Heart Association. Circulation 96:2751-2753, 1997
PubMed
2) American Diabetes Association:Aspirin Therapy in Diabetes. Diabetes Care 26 (suppl 1):S 87-S 88, 2003
 
3) Kimberly RP, Plotz PH:Aspirin induced depression of renal function. N Engl J Med 296:418-424, 1977
PubMed
4) Rowe JW, Andres R, Tobin JD et al:The effect of age on creatinine clearance in man:a cross-sectional and longitudinal study. J Gerontol 31:155-163, 1976
 
5) Nakamura K, Okamura T, Hayakawa T et al;The NIPPON DATA 90 Research Group:Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan:NIPPON DATA 90. Circ J 70:954-959, 2006
 
6) Yasue H, Ogawa H, Tanaka H et al:Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol 83:1308-1313, 1999
PubMed
7) Morimoto T, Nakayama M, Saito Y et al:Aspirin for Primary Prevention of Atherosclerotic Disease in Japan. J Atheroscler Thromb 14:159-166, 2007
PubMed
8) Morgan J, Furst DE:Implications of drug therapy in the elderly. Clin Rheum Dis 12:227-244, 1986
PubMed
9) Koopmans PP, Kateman WG, Tan Y et al:Effects of indomethacin and sulindac on hydrochlorothiazide kinetics. Clin Pharmacol Ther 37:625-628, 1985
PubMed
10) Oates JA:Antagonism of antihypertensive drug therapy by nonsteroidal anti-inflammatory drugs. Hypertension 11:114-116, 1988
 
11) Jackson EK, Oates JA, Branch RA:Indomethacin decreases arterial blood pressure and plasma renin activity in rats with aortic ligation. Circ Res 49:180-185, 1981
PubMed

Chapter6 症例の実際(Q&A)

P.172 掲載の参考文献
1) Chobanian AV, Bakris GL, Black HR et al;National High Blood Pressure Education Program Coordinating Committee:Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
PubMed
2) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
PubMed
3) SHEP Coorperative Research Group:Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program(SHEP). JAMA 265:3255-3264, 1991
 
4) Hansson L, Lindholm LH, Ekbom T et al:Randomized trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
PubMed
5) Pitt B, Zannad F, Remme WJ et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEngl J Med 341:709-717, 1999
 
6) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004. ライフサイエンス出版, 東京, 2004
 
P.175 掲載の参考文献
1) Schulte KL, Meyer-Sabellek W, Rocker L et al:Effects of diltiazem alone and combined with mefruside on cardiovascular response at rest and during exercise, carbohydrate metabolism and serum lipoproteins in patients with systemic hypertension. Am J Cardiol 60:826-831, 1987
PubMed
2) Lacourciere Y, Poirier L, Lefebvre J et al:Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. Am J Hypertens 8 (12 Pt 1):1154-1159, 1995
 
3) Manning G, Millar-Craig MW:Review:calcium antagonists and diuretics; a useful combination in the management of hypertension? J Hum Hypertens 10:441-442, 1996
PubMed
4) Mori H, Ukai H, Yamamoto H et al:Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 29:143-151, 2006
PubMed
5) Wing LM, Reid CM, Ryan P et al:A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in elderly. N Engl J Med 348:583-592, 2003
 
P.181 掲載の参考文献
1) Kaplan NM:Diuretics, Treatment of hypertension:Drug Therapy, Clinical Hypertension 7th Ed., Williams & Wilkins, Baltimore, USA, 1998, pp 189-198
 
2) Turnbull F; Blood Pressure Lowering Treatment Trialists:Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003
PubMed
3) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
PubMed
4) PROGRESS collaborative group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 150 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
PubMed
P.183 掲載の参考文献
1) 福岡富和, 大蔵隆文, 檜垣實男:利尿薬とR-A系抑制薬の併用療法の評価. 循環器科 55:235-242, 2004
 
2) 檜垣實男:わが国における高血圧患者に対する降圧薬併用処方の現状および配合剤の意向調査. Progress in Medicine 26:757-763, 2006
Medical*Online
3) Lindholm LH, Ibsen H, Dahlof B et al:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002
PubMed
4) Physician's Desk Reference, 60th Edition, Thomson, USA, 2006
 
5) 檜垣實男:エビデンスからみたARB/利尿降圧剤への期待. 血圧 13:1349-1353, 2006
 
P.185 掲載の参考文献
1) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretics. JAMA 288:2981-2997, 2002
PubMed
2) Carlsen JE, Kober L, Torp-Pedersen C et al:Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 300:975-978, 1990
PubMed
P.187 掲載の参考文献
1) 河野雄平, 安東克之, 松浦秀夫ほか:食塩制限の必要性と減塩目標. 日本高血圧学会減塩ワーキンググループ報告. 日本高血圧学会, 2006, pp1-12
 
2) Intersalt Cooperative Research Group:Intersalt:an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297:319-328, 1988
 
3) Sacks FM, Svetkey LP, Vollmer WM et al:Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344:3-10, 2001
PubMed
4) Ito K, Kuroda K, Tsuchiyama M et al:Gradient salt reduction and its antihypertensive effect in patients with essential hypertension. Magnesium 1:224-231, 1982
 
5) Eaton SB, Eaton SB 3rd, Konner MJ et al:An evolutionary perspective enhances understanding of human nutritional requirement. J Nutr 126:1732-1740, 1996
PubMed

Chapter7 使用上の注意・薬物相互作用

P.197 掲載の参考文献
1) Orita Y, Fukuhara Y, Nakahama H et al:Enhanced nephrotoxicity of gentamicin by furosemide. Diuretics II:Chemistry, Pharmacology, and Clinical Applications. (Puschett JB, Greenberg A eds) Elsevier Science Publishing Co., Inc., 1987, pp 693-698
 
2) Nakahama H, Obata K, Sugita M et al:Co-administration of furosemide augments tacrolimus-induced impairment in kidney function in rats. Ren Fail 22:525-534, 2000
PubMed
3) Nakahama H, Orita Y, Yamazaki M et al:Pharmacokinetics and pharmacodynamic interaction between furosemide and hydrochlorothiazide in nephrotic patients. Nephron 49:223-227, 1988
PubMed
4) 松本朗, 鈴木洋通, 猿田享男:フロセミド抵抗性浮腫に対するトリパミド (ノルモナール) の併用療法. 診断と治療 82:1041-1045, 1994
 
5) Tanaka M, Oida E, Nomura K et al:The Na+-excreting efficacy of indapamide in combination with furosemide in massive edema. Clin Exp Nephrol 9:122-126, 2005
PubMed
6) Pitt B, Zannad F, Remme WJ et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999
 
7) Juurlink DN, Mamdani MM, Lee DS et al:Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543-551, 2004
PubMed
8) MacKay JH, Arcuri KE, Goldberg AI et al:Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 156:278-285, 1996
PubMed
9) 島田和幸:降圧目標達成のために-ARB/利尿薬合剤の魅力とは-. 血圧 13:36-40, 2006
 

書評

最近チェックした商品履歴

Loading...